MXC Stock Overview
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
MGC Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.011 |
52 Week High | AU$0.032 |
52 Week Low | AU$0.009 |
Beta | 1.28 |
1 Month Change | -8.33% |
3 Month Change | -15.38% |
1 Year Change | -65.63% |
3 Year Change | -66.67% |
5 Year Change | -89.00% |
Change since IPO | -92.41% |
Recent News & Updates
Recent updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Jun 23MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Mar 09Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)
Oct 08If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns
Feb 21What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?
Dec 30Shareholder Returns
MXC | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | 10.0% | -3.6% | 0.8% |
1Y | -65.6% | -29.0% | 2.2% |
Return vs Industry: MXC underperformed the Australian Pharmaceuticals industry which returned -29% over the past year.
Return vs Market: MXC underperformed the Australian Market which returned 2.2% over the past year.
Price Volatility
MXC volatility | |
---|---|
MXC Average Weekly Movement | 16.8% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 8.5% |
10% most volatile stocks in AU Market | 15.5% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: MXC is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: MXC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Roby Zomer | https://mgcpharma.com.au |
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
MGC Pharmaceuticals Limited Fundamentals Summary
MXC fundamental statistics | |
---|---|
Market Cap | AU$32.07m |
Earnings (TTM) | -AU$20.35m |
Revenue (TTM) | AU$4.73m |
6.8x
P/S Ratio-1.6x
P/E RatioIs MXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MXC income statement (TTM) | |
---|---|
Revenue | AU$4.73m |
Cost of Revenue | AU$4.17m |
Gross Profit | AU$562.87k |
Other Expenses | AU$20.91m |
Earnings | -AU$20.35m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -0.007 |
Gross Margin | 11.89% |
Net Profit Margin | -430.00% |
Debt/Equity Ratio | 40.5% |
How did MXC perform over the long term?
See historical performance and comparison